First established by French immunologist Daniel Zagury, M.D, PhD., as a spinoff of Pierre et Marie Curie University. Neovacs became a biotechnology company in 2003 when several investment funds specialized in healthcare industry joined the capital.

Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune diseases.


Our ambition

 “We will focus exclusively on two key priorities: adoption of the Low Lupus Disease Activity State (LLDAS) by health authorities and the value creation of all KINOID technology results both in lupus and preclinical allergy”. Vincent Serra, CEO

Our Pipeline

PIPELINE 710 2 (2)

Where to find us


3-5, Impasse Reille

75014 PARIS



Tel. : 33 (0)1 53 10 93 00

Fax : 33 (0)1 53 10 93 03

Why should you invest in Neovacs?

go to the investors section